This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAdvanced Health Intelligence（AHI）株式概要Operates as a mobile application and technology development company in Australia and internationally. 詳細AHI ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長5/6過去の実績0/6財務の健全性2/6配当金0/6報酬収益は年間178.92%増加すると予測されています リスク分析収益が 100 万ドル未満 ( A$-925K )株式の流動性は非常に低い マイナスの株主資本 過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るAHI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.50該当なし内在価値ディスカウントEst. Revenue$PastFuture-23m2m2016201920222025202620282031Revenue AU$134.6Earnings AU$15.6AdvancedSet Fair ValueView all narrativesAdvanced Health Intelligence Ltd 競合他社HealthLynkedSymbol: OTCPK:HLYKMarket cap: US$6.0mBullfrog AI HoldingsSymbol: NasdaqCM:BFRGMarket cap: US$12.1miCADSymbol: NasdaqCM:ICADMarket cap: US$105.6mCareCloudSymbol: NasdaqGM:CCLDMarket cap: US$96.9m価格と性能株価の高値、安値、推移の概要Advanced Health Intelligence過去の株価現在の株価AU$1.5052週高値AU$15.5252週安値AU$0.64ベータ1.461ヶ月の変化0%3ヶ月変化-2.55%1年変化10.95%3年間の変化n/a5年間の変化n/aIPOからの変化-91.13%最新ニュースお知らせ • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Indexお知らせ • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listingお知らせ • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.お知らせ • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listingお知らせ • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Indexお知らせ • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listingお知らせ • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.お知らせ • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listingお知らせ • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Oct 19Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues.お知らせ • Sep 14Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in fundingAdvanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval.お知らせ • Jun 15Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct ListingNew Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 76% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (76% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$333k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).お知らせ • Dec 20Advanced Health Intelligence Ltd. Announces Board ChangesAdvanced Health Intelligence Ltd. announced some changes at the company's Board of Directors. Former wellteq Digital Health Inc. Chair of the Finance and Audit committee, Ms Jacqueline Yee joins AHI's Board of Directors as a non-executive independent Director with effect from 20 December 2022. Ms Yee has an impressive background having spent over 30 years as an institutional finance professional out of New York, London, Amsterdam, Australia and currently resides in Singapore. Throughout her career to date, Ms Yee has been involved in over $25 billion in transaction value with a notable volume of work in the healthcare sector, including restructuring of 27 national hospitals and the drafting of Healthcare Investment Valuation Policy in New Zealand. With the addition of Ms Yee, Dr. Peter Vaughan has stepped down from the Board with effect from 16 December 2022.お知らせ • Dec 02+ 1 more updateAdvanced Human Imaging Appoints Dr. Peter Vaughan as Non-Executive DirectorAdvanced Human Imaging Limited announced the former Chairman of wellteq, Dr. Peter Vaughan CM, MD, will join the Board of AHI as a non-executive director. Dr. Peter Vaughan, former wellteq chairman is also appointed to the Board of Directors for AHI. Dr. Vaughan has an extensive history in healthcare, corporate and politics recognized by his appointment to the Order of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health". Prior to this he has also held positions as the former Deputy Minister of Health and Wellness, Province of Nova Scotia, an emergency, and family physician and RCAF Flight Surgeon, he also serves as Board Chair of Canada Health Infoway and Chair of the Finance and Audit Committee, Treasurer and Board member of the SCAN-H at the University of Windsor Odette School of Business.お知らせ • Nov 01Advanced Human Imaging Limited announced delayed 20-F filingOn 10/31/2022, Advanced Human Imaging Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Oct 31Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022, at 12:00 W. Australia Standard Time. Location: Lucy Mame meeting room QT Perth Hotel 133 Murray Street, Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2022 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of Remuneration Report; to consider election of Director - Dr Katherine Iscoe; to consider election of Director - Peter Goldstein; to consider re-election of Director - Nicholas Prosser; to consider issue of shares to related party - Nicholas Prosser; and to consider other matters.Seeking Alpha • Sep 02Advanced Human Imaging loses 22% premarket on entering into definitive agreement to acquire wellteq Digital HealthAdvanced Human Imaging (NASDAQ:AHI) plummets 22% pre market on a definitive arrangement agreement with wellteq Digital Health (OTCQB:WTEQF) to acquire all of the outstanding shares of wellteq Digital. Pursuant to the terms of the agreement, wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held. Both the companies have entered into a loan agreement, whereby AHI has agreed to advance to wellteq up to A$1.2M.お知らせ • Jun 29Advanced Human Imaging Ltd Appoints Peter Goldstein as Non-Executive DirectorAdvanced Human Imaging Ltd. announced the appointment of Mr. Peter Goldstein as a non-executive director with effect from June 29, 2022. Mr. Goldstein has over 30 years of diverse and global entrepreneurial, client advisory and capital marketexperience. With a background in international business, he has worked across a range of markets andindustries, holding positions including investment banker, chairman, chief executive officer, director andadvisor to public, private, and emerging growth companies. Mr. Goldstein has achieved capital marketobjectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as hisown entrepreneurial success. He has steered and completed initial public offerings (IPO), up-listing andreverse merger transactions, secured private placements and designed crowdfunding campaigns. Mr. Goldstein founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stopstrategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE andNEO. Mr. Goldstein is the Founder and CEO of Grandview Capital Partners Inc., providing M&A, financial,operational, and organizational consulting services to businesses globally in a wide range of industries. MrGoldstein previously founded Grandview Capital Inc., a boutique investment bank, where he served asmanaging director of investment banking.Mr Goldstein began his entrepreneurial career as the Founder and CEO of a specialty food distributor, whichpioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldsteinhas an MBA in International Business from the University of Miami and held Series 7, 24, 79, 99 and 66registrations with FINRA.Mr. Goldstein has been published across the finance industry as well as featured in Forbes as a member ofthe Forbes Finance Council. Mr. Goldstein, a resident of Florida, U.S.A.お知らせ • Jun 02Advanced Human Imaging Limited to Be Deleted from Other OTCAdvanced Human Imaging Limited's ordinary shares will be deleted from Other OTC effective June 2, 2022. The deletion is due to inactive security.お知らせ • May 28Advanced Human Imaging Limited Announces Resignation of Edward Greissing Jr as DirectorAdvanced Human Imaging Ltd. announced that Mr. Edward Greissing Jr has resigned from the Board of Directors, with effect from 26 May 2022.お知らせ • Feb 16Advanced Human Imaging Limited Appoints Dr. Katherine Iscoe as DirectorAdvanced Human Imaging Limited announced that the appointment of Dr. Katherine Iscoe as director. The date of appointment is February 15, 2022.お知らせ • Feb 15+ 1 more updateAdvanced Human Imaging Limited Announces Executive ChangesAdvanced Human Imaging Limited announced that Dr. Katherine Iscoe, Ph.D., Co-Founder, and former CEO of the company will be rejoining the leadership team as an Executive Director and CEO. The announcements were made as AHI Chairman and CEO, Vlado Bosanac is moving into a strategic role as Head of Strategy and Revenue Growth, effective immediately.株主還元AHIUS Healthcare ServicesUS 市場7D0%0.7%1.2%1Y10.9%-38.4%28.7%株主還元を見る業界別リターン: AHI過去 1 年間で-38.4 % の収益を上げたUS Healthcare Services業界を上回りました。リターン対市場: AHIは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is AHI's price volatile compared to industry and market?AHI volatilityAHI Average Weekly Movementn/aHealthcare Services Industry Average Movement10.5%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: AHI 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のAHIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aScott Montgomerywww.ahi.techもっと見るAdvanced Health Intelligence Ltd 基礎のまとめAdvanced Health Intelligence の収益と売上を時価総額と比較するとどうか。AHI 基礎統計学時価総額US$14.84m収益（TTM）-US$10.94m売上高(TTM)n/a-24.4xP/Sレシオ-1.4xPER（株価収益率AHI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AHI 損益計算書（TTM）収益-AU$924.86k売上原価AU$7.14m売上総利益-AU$8.07mその他の費用AU$8.59m収益-AU$16.66m直近の収益報告Dec 31, 2023次回決算日該当なし一株当たり利益（EPS）-0.068グロス・マージン872.18%純利益率1,800.92%有利子負債／自己資本比率-105.6%AHI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/29 04:55終値2024/01/31 00:00収益2023/12/31年間収益2023/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Advanced Health Intelligence Ltd 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Allen KleeMaxim Group
お知らせ • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Index
お知らせ • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.
お知らせ • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Index
お知らせ • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.
お知らせ • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Oct 19Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues.
お知らせ • Sep 14Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in fundingAdvanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval.
お知らせ • Jun 15Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 76% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (76% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$333k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).
お知らせ • Dec 20Advanced Health Intelligence Ltd. Announces Board ChangesAdvanced Health Intelligence Ltd. announced some changes at the company's Board of Directors. Former wellteq Digital Health Inc. Chair of the Finance and Audit committee, Ms Jacqueline Yee joins AHI's Board of Directors as a non-executive independent Director with effect from 20 December 2022. Ms Yee has an impressive background having spent over 30 years as an institutional finance professional out of New York, London, Amsterdam, Australia and currently resides in Singapore. Throughout her career to date, Ms Yee has been involved in over $25 billion in transaction value with a notable volume of work in the healthcare sector, including restructuring of 27 national hospitals and the drafting of Healthcare Investment Valuation Policy in New Zealand. With the addition of Ms Yee, Dr. Peter Vaughan has stepped down from the Board with effect from 16 December 2022.
お知らせ • Dec 02+ 1 more updateAdvanced Human Imaging Appoints Dr. Peter Vaughan as Non-Executive DirectorAdvanced Human Imaging Limited announced the former Chairman of wellteq, Dr. Peter Vaughan CM, MD, will join the Board of AHI as a non-executive director. Dr. Peter Vaughan, former wellteq chairman is also appointed to the Board of Directors for AHI. Dr. Vaughan has an extensive history in healthcare, corporate and politics recognized by his appointment to the Order of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health". Prior to this he has also held positions as the former Deputy Minister of Health and Wellness, Province of Nova Scotia, an emergency, and family physician and RCAF Flight Surgeon, he also serves as Board Chair of Canada Health Infoway and Chair of the Finance and Audit Committee, Treasurer and Board member of the SCAN-H at the University of Windsor Odette School of Business.
お知らせ • Nov 01Advanced Human Imaging Limited announced delayed 20-F filingOn 10/31/2022, Advanced Human Imaging Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Oct 31Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022, at 12:00 W. Australia Standard Time. Location: Lucy Mame meeting room QT Perth Hotel 133 Murray Street, Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2022 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of Remuneration Report; to consider election of Director - Dr Katherine Iscoe; to consider election of Director - Peter Goldstein; to consider re-election of Director - Nicholas Prosser; to consider issue of shares to related party - Nicholas Prosser; and to consider other matters.
Seeking Alpha • Sep 02Advanced Human Imaging loses 22% premarket on entering into definitive agreement to acquire wellteq Digital HealthAdvanced Human Imaging (NASDAQ:AHI) plummets 22% pre market on a definitive arrangement agreement with wellteq Digital Health (OTCQB:WTEQF) to acquire all of the outstanding shares of wellteq Digital. Pursuant to the terms of the agreement, wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held. Both the companies have entered into a loan agreement, whereby AHI has agreed to advance to wellteq up to A$1.2M.
お知らせ • Jun 29Advanced Human Imaging Ltd Appoints Peter Goldstein as Non-Executive DirectorAdvanced Human Imaging Ltd. announced the appointment of Mr. Peter Goldstein as a non-executive director with effect from June 29, 2022. Mr. Goldstein has over 30 years of diverse and global entrepreneurial, client advisory and capital marketexperience. With a background in international business, he has worked across a range of markets andindustries, holding positions including investment banker, chairman, chief executive officer, director andadvisor to public, private, and emerging growth companies. Mr. Goldstein has achieved capital marketobjectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as hisown entrepreneurial success. He has steered and completed initial public offerings (IPO), up-listing andreverse merger transactions, secured private placements and designed crowdfunding campaigns. Mr. Goldstein founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stopstrategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE andNEO. Mr. Goldstein is the Founder and CEO of Grandview Capital Partners Inc., providing M&A, financial,operational, and organizational consulting services to businesses globally in a wide range of industries. MrGoldstein previously founded Grandview Capital Inc., a boutique investment bank, where he served asmanaging director of investment banking.Mr Goldstein began his entrepreneurial career as the Founder and CEO of a specialty food distributor, whichpioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldsteinhas an MBA in International Business from the University of Miami and held Series 7, 24, 79, 99 and 66registrations with FINRA.Mr. Goldstein has been published across the finance industry as well as featured in Forbes as a member ofthe Forbes Finance Council. Mr. Goldstein, a resident of Florida, U.S.A.
お知らせ • Jun 02Advanced Human Imaging Limited to Be Deleted from Other OTCAdvanced Human Imaging Limited's ordinary shares will be deleted from Other OTC effective June 2, 2022. The deletion is due to inactive security.
お知らせ • May 28Advanced Human Imaging Limited Announces Resignation of Edward Greissing Jr as DirectorAdvanced Human Imaging Ltd. announced that Mr. Edward Greissing Jr has resigned from the Board of Directors, with effect from 26 May 2022.
お知らせ • Feb 16Advanced Human Imaging Limited Appoints Dr. Katherine Iscoe as DirectorAdvanced Human Imaging Limited announced that the appointment of Dr. Katherine Iscoe as director. The date of appointment is February 15, 2022.
お知らせ • Feb 15+ 1 more updateAdvanced Human Imaging Limited Announces Executive ChangesAdvanced Human Imaging Limited announced that Dr. Katherine Iscoe, Ph.D., Co-Founder, and former CEO of the company will be rejoining the leadership team as an Executive Director and CEO. The announcements were made as AHI Chairman and CEO, Vlado Bosanac is moving into a strategic role as Head of Strategy and Revenue Growth, effective immediately.
